Insulet Co. (NASDAQ:PODD) Shares Sold by AMI Asset Management Corp

AMI Asset Management Corp lowered its stake in Insulet Co. (NASDAQ:PODD) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 177,338 shares of the medical instruments supplier’s stock after selling 3,405 shares during the quarter. Insulet comprises about 2.5% of AMI Asset Management Corp’s portfolio, making the stock its 17th biggest holding. AMI Asset Management Corp owned about 0.25% of Insulet worth $46,298,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of PODD. Baillie Gifford & Co. boosted its position in shares of Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock worth $529,669,000 after purchasing an additional 389,639 shares during the period. Geode Capital Management LLC lifted its stake in Insulet by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after purchasing an additional 22,850 shares in the last quarter. Clearbridge Investments LLC boosted its position in shares of Insulet by 6.0% during the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock worth $270,364,000 after buying an additional 75,526 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock valued at $175,697,000 after buying an additional 163,388 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Insulet by 43.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after acquiring an additional 193,839 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PODD shares. Sanford C. Bernstein began coverage on Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. JPMorgan Chase & Co. upped their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Barclays raised their price target on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Morgan Stanley increased their price objective on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Finally, Canaccord Genuity Group boosted their target price on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $272.81.

Insulet Trading Up 1.1 %

NASDAQ PODD opened at $275.81 on Tuesday. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.77. The company has a market capitalization of $19.35 billion, a price-to-earnings ratio of 47.23, a price-to-earnings-growth ratio of 3.46 and a beta of 1.22. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm’s fifty day moving average price is $266.30 and its 200 day moving average price is $233.51.

Insiders Place Their Bets

In other news, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.